Synlogic (SYBX) Competitors $1.43 -0.03 (-2.05%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SYBX vs. ANVS, SLS, BYSI, RVPH, MURA, IMRX, GBIO, HOWL, CNTB, and ELYMShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Annovis Bio (ANVS), SELLAS Life Sciences Group (SLS), BeyondSpring (BYSI), Reviva Pharmaceuticals (RVPH), Mural Oncology (MURA), Immuneering (IMRX), Generation Bio (GBIO), Werewolf Therapeutics (HOWL), Connect Biopharma (CNTB), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Annovis Bio SELLAS Life Sciences Group BeyondSpring Reviva Pharmaceuticals Mural Oncology Immuneering Generation Bio Werewolf Therapeutics Connect Biopharma Eliem Therapeutics Annovis Bio (NYSE:ANVS) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking. Does the media prefer ANVS or SYBX? In the previous week, Annovis Bio had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Annovis Bio and 0 mentions for Synlogic. Annovis Bio's average media sentiment score of 0.38 beat Synlogic's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media. Company Overall Sentiment Annovis Bio Neutral Synlogic Neutral Is ANVS or SYBX more profitable? Annovis Bio's return on equity of 0.00% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A N/A -311.00% Synlogic N/A -207.84%-114.81% Which has preferable valuation & earnings, ANVS or SYBX? Annovis Bio has higher earnings, but lower revenue than Synlogic. Annovis Bio is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$56.20M-$4.46-1.17Synlogic$2.78M6.02-$57.28M-$4.16-0.34 Do analysts rate ANVS or SYBX? Annovis Bio presently has a consensus target price of $31.40, indicating a potential upside of 499.81%. Given Annovis Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Annovis Bio is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Synlogic 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, ANVS or SYBX? Annovis Bio has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ANVS or SYBX? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 32.3% of Annovis Bio shares are owned by company insiders. Comparatively, 3.0% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in ANVS or SYBX? Synlogic received 301 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 96.77% of users gave Annovis Bio an outperform vote while only 69.54% of users gave Synlogic an outperform vote. CompanyUnderperformOutperformAnnovis BioOutperform Votes3096.77% Underperform Votes13.23%SynlogicOutperform Votes33169.54% Underperform Votes14530.46% SummaryAnnovis Bio beats Synlogic on 11 of the 17 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.73M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.3410.0188.8317.53Price / Sales6.02335.351,284.8380.47Price / CashN/A22.6336.6032.90Price / Book0.315.084.964.69Net Income-$57.28M$154.90M$117.89M$224.57M7 Day Performance-0.69%2.59%2.74%3.33%1 Month Performance0.70%1.52%3.63%5.33%1 Year Performance-55.17%5.49%27.26%22.97% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogicN/A$1.43-2.1%N/A-54.5%$16.73M$2.78M-0.346ANVSAnnovis Bio2.2439 of 5 stars$4.77-2.5%$31.40+558.3%-57.1%$65.81MN/A-1.073SLSSELLAS Life Sciences Group0.1965 of 5 stars$0.92-3.4%N/A+101.3%$64.75M$1M-1.3310Gap UpBYSIBeyondSpringN/A$1.64-1.2%N/A+95.0%$64.01M$1.88M0.0080Positive NewsGap DownRVPHReviva Pharmaceuticals3.8045 of 5 stars$1.91+1.6%$11.25+489.0%-56.9%$63.87MN/A-1.725Analyst ForecastOptions VolumeGap UpMURAMural Oncology3.3134 of 5 stars$3.74-3.9%$16.00+327.8%-4.3%$63.66MN/A-0.41119Positive NewsGap DownIMRXImmuneering3.6564 of 5 stars$2.01-2.9%$12.80+536.8%-65.8%$62.41M$320,000.00-1.0260GBIOGeneration Bio4.1972 of 5 stars$0.92-0.6%$6.50+606.5%-45.2%$61.45M$18.58M-0.42150Positive NewsGap UpHOWLWerewolf Therapeutics2.7192 of 5 stars$1.35-2.2%$12.00+788.9%-68.6%$60.16M$3.39M-0.8840Short Interest ↑Positive NewsGap DownCNTBConnect Biopharma3.6203 of 5 stars$1.09+0.5%$8.00+636.9%-1.3%$59.98M$24.12M0.00110News CoveragePositive NewsHigh Trading VolumeELYMEliem TherapeuticsN/A$2.00+7.0%N/A-32.3%$59.50MN/A-3.7720Gap UpHigh Trading Volume Related Companies and Tools Related Companies Annovis Bio Competitors SELLAS Life Sciences Group Competitors BeyondSpring Competitors Reviva Pharmaceuticals Competitors Mural Oncology Competitors Immuneering Competitors Generation Bio Competitors Werewolf Therapeutics Competitors Connect Biopharma Competitors Eliem Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYBX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYBX Stock Alerts